Clinical Research Directory

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Sponsor: Nordic MDS Group

Summary

This study aims to develop highly sensitive methods for early detection of relapse based on the patients unique mutations. Initially, a mutational screen is being performed. Primers directed against these mutations will be constructed and presence of mutations will be followed in bone marrow and blood frequently after transplantation.

Official title: Individual Molecular Minimal Residual Disease (MRD) Monitoring for Patients With MDS and Mixed MDS/MPN Treated With Allogeneic Stem Cell Transplantation

Key Details

Conditions

Locations (8)